Arbutus Biopharma (ABUS) Net Equity Issued and Repurchased (2014 - 2024)

Arbutus Biopharma (ABUS) has reported Net Equity Issued and Repurchased for 10 consecutive years, with $22.4 million the latest figure, recorded in Q2 2024.

• Quarterly Net Equity Issued and Repurchased rose 376.6% year-over-year to $22.4 million in Q2 2024, while the trailing twelve-month figure through Dec 2024 was $44.2 million (up 47.83% YoY) and the FY2024 annual result came in at $44.1 million, up 47.49% from the prior year.
• Net Equity Issued and Repurchased advanced to $22.4 million in Q2 2024 per ABUS's latest filing, from $21.8 million in the prior quarter.
• Over the last five years, Net Equity Issued and Repurchased for ABUS reached as high as $59.3 million in Q4 2021 and fell as low as $300000.0 in Q1 2022.
• A 5-year average of $18.8 million and a median of $16.1 million in 2020 frame the typical range for Net Equity Issued and Repurchased.
• Annual changes were most pronounced in 2022 — Net Equity Issued and Repurchased plunged 98.86% — and 2023, when it soared 6533.33%.
• Year by year, Net Equity Issued and Repurchased stood at $20.2 million in 2020, then soared by 193.76% to $59.3 million in 2021, then tumbled by 80.94% to $11.3 million in 2022, then tumbled by 65.49% to $3.9 million in 2023, then jumped by 474.36% to $22.4 million in 2024.
• According to Business Quant data, Net Equity Issued and Repurchased over the past three periods registered $22.4 million, $21.8 million, and $3.9 million for Q2 2024, Q1 2024, and Q4 2023 respectively.